Tislelizumab combined with GX

Phase 3Small molecule

FFudan University

Tislelizumab combined with GX is one of 14 small molecule programs targeting Tislelizumab. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

TislelizumabRecruiting

TislelizumabPhase 3

Recruiting

Competition

Competitive Landscape

15 competitors in Tislelizumab

#DrugCompanyPhaseTrials

Beyfortus

BeiGene

Phase 2

15 2

Camptosar

Pfizer

Phase 2

1 3

LUNSUMIO

Roche

Phase 2

1 4

Mekinist

Novartis

Phase 2

1 5

Eloxatin

Teva

Phase 2

1 6

Taxol

Teva

Phase 2

1 7

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Phase 2

1 8

Gemzar

Johnson & Johnson

Phase 1

1 9

Anlotinib

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2

1 10

Inderal

WWyeth-Lederle Vaccines

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 3Recruiting

Tislelizumab

NCT06177301

Q4 2030

Phase 3Not yet recruiting

Chemoradiotherapy

NCT07132463

Clinical

Trials by Indication[1]

Tislelizumab1 trial

Tislelizumab Plus GX Versus Tislelizumab Plus GP in the Treatment of R/M NPC

Recruiting·FFudan University·Phase 3·NCT06177301·266 enrolled

Chemoradiotherapy1 trial

Neoadjuvant Chemoradiotherapy Followed by Chemotherapy With or Without Tislelizumab for Resectable Ultra-low Rectal Cancer: The RELIEVE-02 Study

Not yet recruiting·FFudan University·Phase 3·NCT07132463·154 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Tislelizumab combined with GX. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tislelizumab combined with GX compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tislelizumab combined with GX. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Fudan University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: FFudan University

Tislelizumab combined with GX

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q4 2030

Trials by Indication[1]

Tislelizumab1 trial

Chemoradiotherapy1 trial

References

Drug Info

Quick Facts

Related News